Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lights, action, supplements

This article was originally published in The Tan Sheet

Executive Summary

The first spot for the Dietary Supplement Education Alliance's "Just Like Me" campaign will be unveiled to the industry in 30- and 60-second versions during the week of July 16, DSEA says July 2. Director Charles Abehsera, with Back Home Pictures, filmed the ad in the Los Angeles area with a cast and crew of nearly 100. The ad includes an offer of $100 in coupons for consumers (1"The Tan Sheet" June 25, 2007, p. 12). DSEA will air the commercial in test markets before launching the campaign, which also includes print, radio ads and point-of-sale materials, in October in the health food sales channel...

You may also be interested in...

DSEA “Just Like Me” Funding Shifts, Features Added

The Dietary Supplement Education Alliance is changing its paid advertising campaign to promote the industry - including cutting costs by nearly half and allowing participating firms to offers coupons to consumers - to adjust to the loss of support from the largest backer, Leiner Health Products

Boehringer Ingelheim, Gubra Enter Third Obesity Deal

The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.

First Phase III Data For Inovio's Immunotherapy VGX-3100 Encouraging In Cervical Dysplasia

Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts